Track and treat in NSCLC (TATIN) – ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLC - TATI

Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 30 人开始时间: 2019年7月25日最近更新: 2019年11月25日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
入组人数: 30

暂无简介。

•1. Histologically confirmed metastatic NSCLC, characterized by a sensitizing exon 19 deletion or exon 21 L858R EGFR mutation.
•2. WHO performance status 0-2.
•3. Eligible for osimertinib treatment according to the label and according to the treating physician.
•4. Patients must be =18 years of age.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•1. Patients with symptomatic central nervous system metastases who are neurologically unstable. Unstable brain metastases except for those who have completed definitive therapy and have had a stable neurological status for 2 weeks after completion of definitive therapy. Patients may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks prior to the start of study treatment and are clinically asymptomatic.

发起方